Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

Drugs

Volumn 56, Issue 1, 1998, Pages 115-146

  Noble, Stuart ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIVIRAL ACTIVITY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; HEART TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MORTALITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS TRANSPLANTATION; REVIEW;

EID: 0031873744     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856010-00012     Document Type: Review

References (137)

1. Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990 Apr; 39: 597-638
2. Markham A, Faulds D. Ganciclovir: an update of its therapeutic use in cytomegalovirus infection. Drugs 1994 Sep; 48: 455-84
3. Murray RM. Management of cytomegalovirus infection in solid-organ transplant recipients. Immunol Invest 1997; 26 (1-2): 243-55
4. Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patienls with gancilovir. Transplantation 1991 Jan; 51 (1): 98-106
5. Tsimontides AC, Bechlel TP. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation. Ann Pharmacother 1996 Nov; 30: 1277-90
6. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pnemonia after bone marrow transplanlation: where do we stand? Blood 1994 May 1; 83: 2392-8
7. Stratta RJ, Shaeffer MS, Markin RS, et al. Cytomegalovirus infection and disease after liver transplantation: an overview. Dig Dis Sci 1992 May; 37: 673-88
8. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. Hepatology 1993: 18: 185-95, 213779
9. Fietze E, Prösche S, Reinke P, et al. Cytomegalovirus infection in transplant recipients: the role of minor necrosis factor. Transplantation 1994 Sep 27; 58 (6): 675-80
10. Boeckh M, Bowden, R. Cytomegalovirus infection in marrow transplantation Cancer Treat Res 1995; 76: 97-136
11. Ustinov JA, Lahtinen TT, Bruggeman CA, et al. Direct induclion of class II molecules by cytomegalovirus in rat heart microvascular endothelial cells is inhibited by ganciclovir (DHPG). Transplantation 1994 Nov 15; 58: 1027-31
12. Scholz D, Arndt R, Meyer T. Evidence tor an immunosuppressive activity of ganciclovir. Transplant Proc 1994 Dec; 26: 3253-4
13. Rossi S, Schroeder T, Muth K, et al. Serial monitoring of soluble interleukin-2 receptor as a rapid marker of cylomegalovirus infection and response to antiviral therapy. Clin Transpl 1996 Feb; 10 (Pt I): 45-50
14. Li C-R, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994 Apr 1; 83: 1971-9
15. Lemström KB, Brunning JH, Bruggeman CA, et al. Cytomegalovirus infection-enhanced allograft arterioselerosis is prevented by DHPG prophylaxis in the rat. Circulation 1994 Oct; 90: 1969-78
16. Mohacsi PJ, Hulliger B, Wijngaard PLJ. Effects of ganciclovir and acyclovir on vascular cell proliferation of cytomegalovirus-positive and negative donors. Transptlant Proc 1996 Dec; 28: 3234-5
17. Lemström K, Sihvola R, Bruggeman C, et al. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulalion 1997 Jun 17; 95: 2614-6
18. Manion DJ, Vibhagool A, Chou T-C, et al. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. Antiviral Ther 1996 Dec; 1: 237-45
19. Neyts J, De Clercq E. Mycophenolate mofetil markedly enhances the antiviral activity of acyclovir, ganciclovir and penciclovir against herpes simplex virus (wild type and TK strains) and human cytomegalovirus [abstract]. Antiviral Res 1997 Apr; 34: 47
20. Smee DF, Sidwell RW, Barnett BB. Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infection. Antiviral Res 1995; 32: 165-71
21. Smee DF, Sugiyama ST, Sidwell RW, et al. Effects of monoclonal antibody combined with ganciclovir or (S)-1-[3-hydroxy(2-phosphonylmethoxy)-propyl]cytosine against murine cytomegalovirus infections in cell culture and in severe com bined immunodeficient mice. Chemotherapy Basel 1995 Mar-Apr; 41: 141-8
22. Stals FS, Wagenaar SS, Bruggeman CA. Generalized cytomegalovirus (CMV) infection and CMV-induced pneumonitis in the rat: combined effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine and specific antibody treatment. Antiviral Res 1994 Oct; 25: 147-60
23. Stals FS, Wagenaar SS, Kloover JS, et al. Combinations of ganciclovir and antibody for experimental CMV infections. Antiviral Res 1996 Jan; 29: 61-4
24. Kim H-T, Kim D-K, Kim Y-W, et al. Antiviral activity of 9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy]guanine against cytomegalovirus and herpes simplex virus. Antiviral Res 1995 Nov; 28: 243-51
25. Drew WL. Cytomegalovirus resistance to antiviral therapies. Am J Health System Pharm 1996 Apr 15; 53 Suppl. 2, S17-23
26. Chou S, Guentzel S, Michels KR, et al. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995 Jul; 172: 239-42
27. Boivin G, Chou S, Quirk MR, et al. Detection of ganciclovir resistance mutations and quantisation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996 Mar; 173: 523-8
28. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cylomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995 Mar; 171: 576-83
29. Erice A, Gil-Roda C, Pérez J-L, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cyltmegalovirus isolates from immunocompromised patients. J Infect Dis 1997 May; 175: 1087-92
30. Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997 Jul; 176: 69-77
31. Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997 Sep; 176: 786-9
32. Alain S, Honderlick P, Grenet D, et al. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 1997 May 27; 63: 1533-6
33. Lurain NS, Ammons HC, Kapell KS, et al. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 1996 Aug 27; 62: 497-502
34. Rosen HR, Benner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection alter liver transplantation. Transplantation 1997 Feb 15; 63: 476-8
35. Reusser P, Hostettler B, Atenhofer R, Ganciclovir-resistant cytomegalovirus infection: two cases with different clinical impact [in German]. Schweiz Med Wochenschr 1446 Oct 19: 126: 1779-84
36. Slavin MA, Bindra RR, Gleaves CA, et al. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993; 37 (6): 1360-3
37. Jahs DA, Enger C, Dunn JR et al. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 1998: 177: 770-3
38. Grossi P, Baldanti F. Treatment of ganciclovir-resistant human cytomegalovirus infection. J Nephrol 1997 May-Jun: 10: 146-51
39. Baldanti F, Sarasini A, Silini E, et al. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible tor ganciclovir- and foscarnet-specific resistance, respectively. Scand J Infect Dis 1995 Suppl. 99: 103-4
40. Garey KW, Tornatore KM, Saigal N, et al. Pharmacokinetics of ganciclovir in renal transplant recipients with cytomegalovirus [abstract]. Pharmacotherapy 1997 Sep-Oct; 17: 1120
41. Anderson RD, Gains GK, Jung D, et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995 May-Jun; 17: 428-32
42. Venuto RC, Tornatore K, Garey K, et al. Ganciclovir pharmacokinetics (PK) and cylokine profiles in renal transplant patients (RTR) with cytomegalovirus infection [abstract]. J Invest Med 1497 Sep: 345A
43. Pescovitz MD, Brook B, Jindal RM, et al. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. Clin Transpt 1997; 11: 613-7
44. Reina J. Mechanisms of resistance to antiviral agents in the herpesvirus group [in Spanish]. Enferm Infecc Microbiol Clin 1997 Jun-Jul; 15: 329-34
45. Wolfe FJ, Mathur V, Tomlanovich S, et al. Pharmacokinetics of myeophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy 1997; 17 (3): 591-8
46. ® (ganciclovir capsules). Prescribing information. Nutley (NJ). USA, 1946
47. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118 (3): 173-8
48. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118(3): 179-84
49. Boeckh M, Gooley TA, Myersoni D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment wilh ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind sludy. Blood 1996 Nov 15; 88 (10): 4063-71
50. Pineiro L, Skettino S, Tan J, et al. Efficacy of oral ganciclovir (GAN) for prevention of CMV infection following allogeneic bone marrow transplantation (BMT) [abstract]. 39th Meeting, American Society of Hematology; 1997 Dec 5-9; San Diego
51. Atkinson K, Arthur C, Bradstock K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune suppressed HLA-identical unrelated donor marrow transplant recipients. Bone Marrow Transplant 1995 Sep; 16: 401-1
52. Brohi S, Chadrasekar PH, BMT Team. Twice weekly ganciclovir prophylaxis against cytomegalovirus disease in allogeneic bone marrow transplantation recipients [abstract no. 152]. 9th International Symposium on Infections in the Immunocopromised Host; 1996 Jun 23-26; Assisi
53. Maltezou HC, Whimbey E, Champlin RE, et al. Comparison of two ganciclovir regimens for the prevention of CMV disease in adult allogeneic hone marrow transplant recipients [abstract). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18: New Orleans: 168
54. Toze CL, Shepherd JD, Sherlock CH, et al. Cytomegalovirus (CMV) disease (D) in allogeneic bone marrow transplant (BMT) recipients: effectiveness ot ganciclovir prophylactic strategy, characterization of CMVD risk factors, and comparison to historical controls [abstract]. Blood 1995 Nov 15; 86 Suppl. 1: 968a
55. Goodrich JM, Mori M, Gleaves CA, et al. Karly treatment with ganciclovir to present cytomegalovirus disease aftrer allogeneic bone marrow transplantation. N Engl J Med 1991; 325 (23): 1601-7
56. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants N Engl J Med 1991; 324 (15): 1005-11
57. Zaia JA, Chao NJ, Rizk NW, et al. A random trial of 12 week vs 6-week preemptive ganciclovir therapy in allogeneic marrow transplantation: interim analysis [abstract]. Blood 1996 Nov 15; 88 Suppl. 1: 423a
58. Baltathakis I, Gougopoulou D, Kolovou A, et al. Short duration preemptive treatment wth ganciclovir for the management of cylomegalovirus infection after allogeneic bone marrow transplantation [abstract no, P643]. Bone Marrow Transplant 1997; 19 Suppl. 1: S161
59. Einsele H, Hebart H, Klingebiel T, et al. PCR-directed preemptive therapy with ganciclovir prevents CMV associated mortality [abstract]. Bone Marrow Transplant 1996 Mar: 17 Suppl. 1: S92
60. Ljungman P, Loré K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996 Apr; 17: 583-7
61. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic hone marrow transplantation, role of early antiviral treatment for HCMV antigenaemia on patients' outcome. Br J Haematol 1994 Sep; 88: 64-71
62. Singhal S, Mehta J, Powles R, et al. Three weeks of ganciclovir for cylomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995 May; 15: 777-81
63. Zaia JA, Schmidt GM, Chao NJ, et al. Use of preemptive ganciclovir based solely on asymptomatic pulmonary cytomegalovinis infection in marrow transplant recipients: long-term follow up [abstract]. Blood 1994 Nov 15: 84 Suppl. 1: 249a
64. Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnetganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996 Aug 15: 62: 376-80
65. Moretti S, Bacigalupo A, Tedone E, et al. Combined foscarnet and ganciclovir for CMV infections post marrow transplantation: dose administered, efficacy and adverse evenis [abstract]. Bone Marrow Transplant 1947 Mar; 19 Suppl. 1: S163
66. Cohen AT, O'Grady JG, Sutherland S, et al. Controlled trial of prophylactic versus theapeutic use of ganciclovir after liver transplantation. J Med Virol 1993, 40: 5-9
67. Gane E, Saliba F, Valdecasas GJC, et al, Randomised trial of efficacy and safely of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997 Dec 13; 350: 1729-33
68. Badley AD, Seaberg EC, Porayko MK, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. Transplanlation 1997 Jul 15; 64: 66-73
69. Martin M, Mañez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994 Oct 15; 58: 779-85
70. Green M, Kaufmann M, Wilson J, et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cylomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997 Dec: 25: 1344-9
71. Winston DJ, Wirin D, Shaked A. Randomised comparison of ganeiclovir and high-dose acyclovir for long-term cylomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995 Jul 8; 346: 69-74
72. King SM, Superina R, Andrews W, et al, Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus diseuse in children receiving liver transplants. Clin Infect Dis 1997 Nov; 25: 1173-9
73. Winston DJ, Imagawa DK, Holt CD, et al. Long-term ganciclovir prophylaxis eliminates serious cytoinegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995 Dec 15; 60: 1357-60
74. Ham JM, Shelden SL, Godkin RR, et al. Cytomegalovirus pro phylaxis with ganciclovir, acyclovir, and CMV hyperimimine globulin in liver transplant patients receiving OKT3 induction. Transplant Proc 1995 Oct; 27 Suppl. 1: 31-3
75. Singh N, Yu VL, Mieles L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent eytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994 Mar 1: 120: 375-81
76. Singh N, Yu VL, Gayowski T, et al. CMV antigenemia directed preemptive prophylaxis with oral ganciclovir for the prevention of CMV disease in liver transplant recipients: a prospective, randomized, controlled trial [abstract]. 17th Annual Meeting, American Society of Transplant Physicians; 1998 May 9-13; Chicago
77. Lautenschlager I, Hockerstedt K, Salmela K, Quantitative CMV-antigenemia test in the diagnosis of CMV infection and in the monitoring of response to antiviral treatment in liver transplant recipients. Transplant Proc 1994 Jun; 26: 1719-20
78. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996 Jun 15; 61: 1659-60
79. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992 Apr 30; 326 (18): 1182-6
80. Macdonald PS, Keogh AM, Marshman D, et al. A double-blind placebo-controlled trial of low-dose gunciclovir to prevent cytomegalovirus disease alter heart transplantation. J Heart Lung Transplant 1995 Jan-Feb; 14: 32-8
81. Aguado JM, Gomez-Sandiez MA, Lumbreras C, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immuunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995 Jul; 39: 1643-5
82. Mullen GM, Silver MA, Lawless CE, et al. Oral ganciclovir prophylaxis reduces cylomegalovirus disease during the lirst year after heart transplantation [abstract no. 1071-56]. J Am Coll Cardiol 1998; 31 Suppl. 2A: 157A
83. Valenza M, Czer LSC, Pan S-H, et al. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. J Heart Lung Transplant 1995 Jul-Aug; 14: 659-65
84. Kelly JL, Albert RK, Wood DE, et al. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995 Apr 27; 59: 1144-7
85. Lackner RP, Thompson JT, Egan TM, et al. The role of gancyclovir prophylaxis in a lung transplant (LTX) program [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2): 524
86. Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994 Jul; 150: 146-52
87. Gavalda J, Roman A, Bravo C, et al. Protective effect of ganciclovir (G) against cytomegalovirus (CMV) pneumonitis and acute rejection (AR) in lung transplant patients (LTp) [abstract H122]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, 201
88. Hertz M, Fox J, King M, et al. A randomized study of three times weekly vs, daily ganciclovir for CMV prevention after lung transplantation [abstract]. J Heart Lung Transplant 1995 Jan-Feb; 14 (Pt 2): S67
89. Poirier CD, Doyle RL, Theodore J, et al. Comparison between CMV hyperimmune globulin and ganciclovir tor CMV prophylaxis in heart-lung and lung transplant recipient [abstract no. 211]. J Heart Lung Transplant 1998 Apr; 17 (1): 96
90. Gutiérrez CA, Chaparro C, Krajden M, et al. Cytomegalovirus prophylaxis with ganciclovir and immune globulin in lung transplant recipients [abstract]. Chest 1997 Sep; 112 Suppl.: 105S
91. Zamora MR, Fullerton DA, Campbell DN, et al. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Transplant Proc 1994 Oct; 26 Suppl. 1: 49-51
92. Rondeau E, Bourgeon B, Peraldi MN, et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858-62
93. Ahsan N, Holman MJ, Yang HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transpl 1997 Dec; 11: 633-9
94. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplanlation 1997 Dec 27; 64: 1843-6
95. Conti DJ, Freed BM, Singh TP, et al. Preemptive ganciclovir therapy in cytomegalovirus-seropositivE renal transplants recipients. Arch Surg 1995 Nov; 130: 1217-22
96. Hibhberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995 Jul 1; 123: 18-26
97. Pouteil-Noble C, Megas F, Chapuis F, et al. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Transplant Proc 1996 Oct; 28: 2811
98. Conti DJ, Freed BM, Gruber SA, et al. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: a trial of ganciclovir vs immunoglobulin. Arch Surg 1994 Apr; 129: 443-7
99. Stratta RJ, Taylor RJ, Bynon JS, et al. Viral prophylaxis in combined pancreas-kidney transplant recipients. Transplantation 1994 Feb; 57 (4): 506-12
100. Hopt UT, Pfeffer F, Schareck W, et al. Ganciclovir for prophylaxis ot CMV disease afler pancreas/kidney transplantation. Transplant Proc 1994 Apr; 26: 434-5
101. Gómez E. de Oña M, Aguado S, et al. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3. Nephron 1996 Oct; 74: 367-72
102. Peddi VR, Hariharan S, Schroeder TJ, et al. Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts. Nephron 1997 May; 76: 49-55
103. Shen GK, Alfrey FJ, Knoppel CL, et al. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation. Transplantation 1997 Sep 27; 64: 931-3
104. Akposso K, Rondeau H, Haymann J-P, et al. Long-term prognosis of renal transplantation after preemptive treatment of cylomegalovirus infection. Transplantation 1997 Apr 15; 63: 974-6
105. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cvtomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1996; 8: 118-25
106. Kohli V, Velosa J, Sterioff S, et al. Prophylaxis for cytomegalovirus in pancreas transplant recipients using intravenous ganciclovir. Transplant Proc 1995 Dec; 27: 2993
107. Harland RC, Vermin WB, Bunzendahl H, et al. Ganciclovir/ acyclovir prophylaxis reduces the incidence of cytomegalovirus injections in pancreas transplant recipients. Transplant Proc 1994 Apr; 26: 432-3
108. Abecassis MM, Koffron AJ, Kaplan B, et al. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 1997 Jan 27; 63: 275-9
109. Mañez R, St GK, Linden P, et al. Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis. J Ciln Microbiol 1994 Nov; 32: 2655-9
110. Aspin MM, Gallez-Hawkins GM, Giugni TD, et al. Comparison of plasma PCR and bronchoalveolar lavage fluid culture for defection of cytomegalovirus infection in adult bone marrow transplant recipients. J Clin Microbiol 1994 Sep; 32: 2266-9
111. Hebart H, Kanz L, Jahn G, et al. Management of cytomegalo-virus infection after solid-organ or stem-cell transplantation: current guidelines and future prospects. Drugs 1998 Jan; 55: 59-72
112. Goodrich JM, Bocckh M, Bowden R, Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994 Aug; 19: 287-98
113. Roberts TC, Buller RS, Gaudreault-Keener M, et al. Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR. J Clin Microbiol 1997 Sep; 35 (9): 2224-8
114. Schäfer P, Tenschert W, Gutensohn K, et al. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigen assay. J Clin Microbiol 1997 Mar; 35 (3): 741-4
115. Gozlan J, Salord J-M, Chouaid C, et al. Human cytomegalovirus (HCMV) late-mRNA detection in peripheral blood of AIDS patients: diagnostic value for HCMV disease compared with those of viral culture and HCMV DNA detection. J Clin Microbiol 1993; 31 (7): 1943-5
116. Macartney M, Gane EJ, Portmann B, et al. Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods, Transplanlation 1997 Jun 27; 63 (12): 1803-7
117. Patel R, Wiesner RH, Paya CV. Prophylaxis and treatment of cytometalovirus infection after solid organ transplantation. Clin Immunother 1996 Jan; 5: 13-29
118. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996 May 15; 61: 1279-89
119. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cylomegalovirus disease in transplant recipients. Clin Transpl 1994; 8: 10-8
120. Badas A, Stoukides CA. Guidelines for prophylaxis of cytomegalovirus disease in bone marrow transplant patients. Ann Pharmacother 1996 Dec; 30: 1483-6
121. Tsevat J, Snydman DR, Paukci SG, et al. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. Transplantation 1991 Aug; 52 (2): 259-65
122. Reusser P. Human cytomegalovirus infection and disease after bone marrow and solid organ transplantation. Baillière's Clin Infect Dis 1996 Nov; 3 (3): 357-64
123. Prentice HG, Gluckman H, Powles RL, et al. Impact of long-term acyclovir on cylomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994 Mar 26; 343: 749-53
124. Meyers JD, Reed EC, Shepp DH, et al Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow trasnplantalion. N Engl J Med 1988; 318: 70-5
125. Zaia JA. Prophylaxis and treatment of CMV infections in transplantation. Adv Exp Med Biol 1996; 394: 117-34
126. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines tor the management of autologous and allogeneic hone marrow transplantation. Ann Intcrn Med 1994: 120: 143-58
127. Volpi A, Gentile G. Future directions on prophylaxis and therapy of cytomegalovirus diseases. Int J Antimicrob Agents 1996 Oct; 7: 287-91
128. Griffiths PD. Prophylaxis against CMV infections in transplant patients. J Antimicrob Chemother 1997 Mar; 39: 299-301
129. Prenticc HG, Kho R. Clinical strategics for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant, Bone Marrow Transplant 1997 Jan; 19 (2): 135-42
130. Balfour Jr HH, Chace HA, Stapleton JT, et al. A ramlomized placebo-controlled trial of oral acyelovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381
131. Kletzmayr J, Kotzmann H, Popow-Kraupp T, et al. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996 Feb; 7: 325-30
132. Bailey TC, Ettinger NA, Storch GA, et al. failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegaolovirus disease in recipients of solid organ transplants. Am J Med 1993 Sep; 95; 273-8
133. Marker SC, Howard R, Simmons R, et al. Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery 1980; 89 (6): 660-71
134. Lewis RM, Johnson PC, Golden D, et al. The adverse impact of Cytomegalovirus infection on clinical outcome in cyctosporine-prednisone treated renal allograft recipients. Transplantation 1988; 45 (2): 353-4
135. McCarthy JM, Karim MA, Krueger H, et al. The cost impact of Cytomegalovirus disease in renal transplant recipients. Transplantation 1993 Jun; 555 (6): 1277-82
136. Goodrich J, Khardori N. Cytomegalovirus: the taming of the beast? Lancet 1997 Dec 13; 350: 1718-9
137. Brown F, Arum I, Francis G, et al. Ganciclovir prodrug (RS-79070) - multiple dose, dose-ranging study with effect of food [abstract]. 4th Conferenee on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, D.C.